GlassScriptPhysician profile
Bridgette Rose Gauslin
NPI 1518679943
$1,566.30
in general payments reported to CMS, 2019-2025
20 companies · $689 in 2025
The $689 reported for 2025 was more than what 78% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.30 · 2023: $603 · 2024: $254 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,546.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $466.89 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $253.18 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $126.71 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lundbeck LLC | $99.91 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $88.99 | 2023-2025 | Mounjaro, Amyvid, Kisunla |
| Glaxosmithkline, LLC. | $74.73 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $73.39 | 2025 | |
| Corcept Therapeutics | $67.22 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.39 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $36.88 | 2025 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $32.08 | 2025 | Nuzyra, Xhance |
| Exact Sciences Corporation | $28.33 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $28.17 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $27.12 | 2025 | Voquezna |
| Philips North America LLC | $20.30 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $19.70 | 2025 | Novasure |
| Verona Pharma, INC. | $18.58 | 2025 | Ohtuvayre |
| Pfizer INC. | $15.75 | 2025 | |
| Vanda Pharmaceuticals INC. | $15.58 | 2025 | Fanapt |
| Kowa Pharmaceuticals America, INC. | $14.40 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridgette Gauslin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.